

## Ezetimibe / Simvastatin Formulation

Version 5.2      Revision Date: 06.04.2024      SDS Number: 28136-00023      Date of last issue: 30.09.2023  
Date of first issue: 04.11.2014

---

**Section 1: Identification**

**Product identifier** : Ezetimibe / Simvastatin Formulation

**Recommended use of the chemical and restrictions on use**

Recommended use : Pharmaceutical  
Restrictions on use : Not applicable

**Manufacturer or supplier's details**

Company : Organon & Co.  
Address : 30 Hudson Street, 33rd floor  
Jersey City, New Jersey, U.S.A 07302  
Telephone : +1-551-430-6000  
Emergency telephone number : +1-215-631-6999  
E-mail address : EHSSTEWARD@organon.com

---

**Section 2: Hazard identification****Classification of the substance or mixture**

Skin corrosion/irritation : Category 2  
Skin sensitisation : Category 1  
Specific target organ toxicity - repeated exposure : Category 1 (Liver, muscle, optic nerve, Eye)  
Long-term (chronic) aquatic hazard : Category 2

**GHS Label elements, including precautionary statements**

Hazard pictograms : 

Signal word : Danger

Hazard statements : H315 Causes skin irritation.  
H317 May cause an allergic skin reaction.  
H372 Causes damage to organs (Liver, muscle, optic nerve, Eye) through prolonged or repeated exposure.  
H411 Toxic to aquatic life with long lasting effects.

## Ezetimibe / Simvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023  |
| 5.2     | 06.04.2024     | 28136-00023 | Date of first issue: 04.11.2014 |

Precautionary statements :

**Prevention:**

P260 Do not breathe dust.  
P264 Wash skin thoroughly after handling.  
P270 Do not eat, drink or smoke when using this product.  
P272 Contaminated work clothing should not be allowed out of the workplace.  
P273 Avoid release to the environment.  
P280 Wear protective gloves.

**Response:**

P302 + P352 IF ON SKIN: Wash with plenty of water.  
P314 Get medical advice/ attention if you feel unwell.  
P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention.  
P362 + P364 Take off contaminated clothing and wash it before reuse.  
P391 Collect spillage.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards which do not result in classification**

Dust contact with the eyes can lead to mechanical irritation.  
May form explosive dust-air mixture during processing, handling or other means.

**Section 3: Composition/information on ingredients**

Substance / Mixture : Mixture

**Components**

| Chemical name      | CAS-No.     | Concentration (% w/w) |
|--------------------|-------------|-----------------------|
| Cellulose          | 9004-34-6   | >= 10 -< 20           |
| Ezetimibe          | 163222-33-1 | >= 10 -< 20           |
| Simvastatin        | 79902-63-9  | >= 10 -< 20           |
| Magnesium stearate | 557-04-0    | >= 1 -< 10            |

**Section 4: First-aid measures****Description of necessary first-aid measures**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
Get medical attention if symptoms occur.

In case of skin contact : In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.  
Get medical attention.

## Ezetimibe / Simvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023  |
| 5.2     | 06.04.2024     | 28136-00023 | Date of first issue: 04.11.2014 |

---

Wash clothing before reuse.  
Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention if symptoms occur.  
Rinse mouth thoroughly with water.

**Most important symptoms and effects, both acute and delayed**

Risks : Causes skin irritation.  
May cause an allergic skin reaction.  
Causes damage to organs through prolonged or repeated exposure.  
Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

**Indication of any immediate medical attention and special treatment needed**

Treatment : Treat symptomatically and supportively.

---

**Section 5: Fire-fighting measures****Extinguishing media**

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

**Special hazards arising from the substance or mixture**

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Nitrogen oxides (NO<sub>x</sub>)  
Fluorine compounds  
Metal oxides

**Special protective actions for fire-fighters**

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

## Ezetimibe / Simvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023  |
| 5.2     | 06.04.2024     | 28136-00023 | Date of first issue: 04.11.2014 |

---

---

**Section 6: Accidental release measures****Personal precautions, protective equipment and emergency procedures**

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

**Environmental precautions**

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

**Methods and materials for containment and cleaning up**

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

**Section 7: Handling and storage****Precautions for safe handling**

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not get on skin or clothing.  
Do not breathe dust.  
Do not swallow.  
Avoid contact with eyes.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Do not eat, drink or smoke when using this product.

## Ezetimibe / Simvastatin Formulation

Version 5.2      Revision Date: 06.04.2024      SDS Number: 28136-00023      Date of last issue: 30.09.2023  
Date of first issue: 04.11.2014

Hygiene measures : Take care to prevent spills, waste and minimize release to the environment.  
: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Contaminated work clothing should not be allowed out of the workplace.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**Conditions for safe storage, including any incompatibilities**

Conditions for safe storage : Keep in properly labelled containers.  
Store in accordance with the particular national regulations.  
Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

**Section 8: Exposure controls/personal protection****Control parameters****Occupational Exposure Limits**

| Components         | CAS-No.                   | Value type (Form of exposure)       | Control parameters / Permissible concentration | Basis    |
|--------------------|---------------------------|-------------------------------------|--|----------|
| Cellulose          | 9004-34-6                 | PEL (long term)                     | 10 mg/m <sup>3</sup>                           | SG OEL   |
|                    |                           | TWA                                 | 10 mg/m <sup>3</sup>                           | ACGIH    |
| Ezetimibe          | 163222-33-1               | TWA                                 | 25 µg/m <sup>3</sup> (OEB 3)                   | Internal |
|                    |                           | Wipe limit                          | 250 µg/100 cm <sup>2</sup>                     | Internal |
| Simvastatin        | 79902-63-9                | TWA                                 | 25 µg/m <sup>3</sup> (OEB 3)                   | Internal |
|                    | Further information: DSEN |                                     |  |          |
|                    |                           | Wipe limit                          | 250 µg/100 cm <sup>2</sup>                     | Internal |
| Magnesium stearate | 557-04-0                  | PEL (long term)                     | 10 mg/m <sup>3</sup>                           | SG OEL   |
|                    |                           | TWA (Inhalable particulate matter)  | 10 mg/m <sup>3</sup>                           | ACGIH    |
|                    |                           | TWA (Respirable particulate matter) | 3 mg/m <sup>3</sup>                            | ACGIH    |

**Appropriate engineering control measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

## Ezetimibe / Simvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023  |
| 5.2     | 06.04.2024     | 28136-00023 | Date of first issue: 04.11.2014 |

---

protect products, workers, and the environment.  
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

**Individual protection measures, such as personal protective equipment (PPE)**

- |                        |   |  |
|------------------------|---|--|
| Eye/face protection    | : | Wear safety glasses with side shields or goggles.<br>If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.<br>Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols. |
| Skin protection        | : | Work uniform or laboratory coat.<br>Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.<br>Use appropriate degowning techniques to remove potentially contaminated clothing.                    |
| Respiratory protection | : | If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.   |
| Filter type            | : | Particulates type  |
| Hand protection        | : |  |
| Material               | : | Chemical-resistant gloves  |
| Remarks                | : | Consider double gloving.   |
- 

**Section 9: Physical and chemical properties**

- |   |   |                   |
|---|---|-------------------|
| Appearance                              | : | powder            |
| Colour                                  | : | No data available |
| Odour                                   | : | No data available |
| Odour Threshold                         | : | No data available |
| pH                                      | : | No data available |
| Melting point/freezing point            | : | No data available |
| Initial boiling point and boiling range | : | No data available |
| Flash point                             | : | No data available |
| Evaporation rate                        | : | No data available |

## Ezetimibe / Simvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023  |
| 5.2     | 06.04.2024     | 28136-00023 | Date of first issue: 04.11.2014 |

---

|  |   |   |
|--|---|---|
| Flammability (solid, gas)                        | : | May form explosive dust-air mixture during processing, handling or other means. |
| Flammability (liquids)                           | : | No data available   |
| Upper explosion limit / Upper flammability limit | : | No data available   |
| Lower explosion limit / Lower flammability limit | : | No data available   |
| Vapour pressure                                  | : | No data available   |
| Relative vapour density                          | : | No data available   |
| Relative density                                 | : | No data available   |
| Solubility(ies)                                  |   |   |
| Water solubility                                 | : | No data available   |
| Partition coefficient: n-octanol/water           | : | No data available   |
| Auto-ignition temperature                        | : | No data available   |
| Decomposition temperature                        | : | No data available   |
| Viscosity  |   |   |
| Viscosity, kinematic                             | : | No data available   |
| Explosive properties                             | : | Not explosive   |
| Oxidizing properties                             | : | The substance or mixture is not classified as oxidizing.                        |
| Molecular weight                                 | : | No data available   |
| Particle characteristics                         |   |   |
| Particle size                                    | : | No data available   |

---

**Section 10: Stability and reactivity**

|                                    |   |  |
|------------------------------------|---|--|
| Reactivity                         | : | Not classified as a reactivity hazard.   |
| Chemical stability                 | : | Stable under normal conditions.  |
| Possibility of hazardous reactions | : | May form explosive dust-air mixture during processing, handling or other means.<br>Can react with strong oxidizing agents. |
| Conditions to avoid                | : | Heat, flames and sparks.<br>Avoid dust formation.  |
| Incompatible materials             | : | Oxidizing agents   |

## Ezetimibe / Simvastatin Formulation

Version 5.2      Revision Date: 06.04.2024      SDS Number: 28136-00023      Date of last issue: 30.09.2023  
Date of first issue: 04.11.2014

---

Hazardous decomposition products : No hazardous decomposition products are known.

---

**Section 11: Toxicological information**

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Not classified based on available information.

**Components:****Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

**Ezetimibe:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
LD50 (Mouse): > 5,000 mg/kg  
LD50 (Dog): > 3,000 mg/kg  
Acute inhalation toxicity : Remarks: No data available  
Acute dermal toxicity : Remarks: No data available  
Acute toxicity (other routes of administration) : LD50 (Rat): > 2,000 mg/kg  
Application Route: Intraperitoneal  
LD50 (Mouse): > 1,000 - < 2,000 mg/kg  
Application Route: Intraperitoneal

**Simvastatin:**

Acute oral toxicity : LD50 (Rat): 5,000 mg/kg  
LD50 (Mouse): 3,800 mg/kg

**Magnesium stearate:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 423  
Assessment: The substance or mixture has no acute oral toxicity



## Ezetimibe / Simvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023  |
| 5.2     | 06.04.2024     | 28136-00023 | Date of first issue: 04.11.2014 |

---

Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg  
Remarks: Based on data from similar materials

**Skin corrosion/irritation**

Causes skin irritation.

**Components:****Ezetimibe:**

Species : Rabbit  
Result : No skin irritation

**Simvastatin:**

Species : Rabbit  
Remarks : Moderate skin irritation

**Magnesium stearate:**

Species : Rabbit  
Result : No skin irritation  
Remarks : Based on data from similar materials

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Ezetimibe:**

Species : Rabbit  
Result : No eye irritation

**Simvastatin:**

Species : Rabbit  
Remarks : slight irritation

**Magnesium stearate:**

Species : Rabbit  
Result : No eye irritation  
Remarks : Based on data from similar materials

**Respiratory or skin sensitisation****Skin sensitisation**

May cause an allergic skin reaction.

**Respiratory sensitisation**

Not classified based on available information.

## Ezetimibe / Simvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023  |
| 5.2     | 06.04.2024     | 28136-00023 | Date of first issue: 04.11.2014 |

---

**Components:****Ezetimibe:**

Test Type : Maximisation Test  
 Species : Guinea pig  
 Result : negative

**Simvastatin:**

Assessment : Probability or evidence of skin sensitisation in humans  
 Result : positive

**Magnesium stearate:**

Test Type : Maximisation Test  
 Exposure routes : Skin contact  
 Species : Guinea pig  
 Method : OECD Test Guideline 406  
 Result : negative  
 Remarks : Based on data from similar materials

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Cellulose:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
 Result: negative  
 Test Type: In vitro mammalian cell gene mutation test  
 Result: negative  
 Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
 Species: Mouse  
 Application Route: Ingestion  
 Result: negative

**Ezetimibe:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
 Metabolic activation: with and without metabolic activation  
 Result: negative  
 Test Type: Chromosomal aberration  
 Test system: Human lymphocytes  
 Result: negative  
 Genotoxicity in vivo : Test Type: Micronucleus test  
 Species: Mouse  
 Cell type: Bone marrow  
 Application Route: Oral

## Ezetimibe / Simvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue:             |
| 5.2     | 06.04.2024     | 28136-00023 | 30.09.2023                      |
|         |                |             | Date of first issue: 04.11.2014 |

---

Result: negative

**Simvastatin:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Alkaline elution assay  
Result: negative

Test Type: Chromosomal aberration  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Application Route: Oral  
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

**Magnesium stearate:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
Remarks: Based on data from similar materials

**Carcinogenicity**

Not classified based on available information.

**Components:****Cellulose:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 72 weeks  
Result : negative

**Ezetimibe:**

Species : Rat, female

## Ezetimibe / Simvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023  |
| 5.2     | 06.04.2024     | 28136-00023 | Date of first issue: 04.11.2014 |

---

Application Route : oral (feed)  
 Exposure time : 104 weeks  
 Result : negative

Species : Rat, male  
 Application Route : oral (feed)  
 Exposure time : 104 weeks  
 Result : negative

Species : Mouse  
 Application Route : oral (feed)  
 Exposure time : 104 weeks  
 Result : negative

**Simvastatin:**

Species : Mouse  
 Application Route : Oral  
 Exposure time : < 92 weeks  
 Target Organs : Harderian gland  
 Tumor Type : Liver, Lungs  
 Remarks : The significance of these findings for humans is not certain.

Species : Rat  
 Application Route : Oral  
 Exposure time : 2 Years  
 Tumor Type : Liver, Thyroid  
 Remarks : The significance of these findings for humans is not certain.

**Reproductive toxicity**

Not classified based on available information.

**Components:****Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative

**Ezetimibe:**

Effects on fertility : Test Type: Fertility/early embryonic development  
 Species: Rat, male and female  
 Fertility: NOAEL: > 1,000 mg/kg body weight  
 Result: No effects on fertility, No fetotoxicity

Effects on foetal development : Test Type: Development

## Ezetimibe / Simvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023  |
| 5.2     | 06.04.2024     | 28136-00023 | Date of first issue: 04.11.2014 |

---

ment

Species: Rat  
 Application Route: Oral  
 Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight  
 Result: No adverse effects

Test Type: Development  
 Species: Rabbit  
 Application Route: Oral  
 Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight  
 Result: No adverse effects

**Simvastatin:**

Effects on fertility

: Test Type: Fertility  
 Species: Rat, male  
 Application Route: Oral  
 Fertility: LOAEL: 25 mg/kg body weight

Effects on foetal development

: Test Type: Embryo-foetal development  
 Species: Rat  
 Application Route: Oral  
 Embryo-foetal toxicity: NOAEL: 25 mg/kg body weight  
 Result: No teratogenic effects, No adverse effects

Test Type: Embryo-foetal development  
 Species: Rabbit  
 Application Route: Oral  
 Embryo-foetal toxicity: NOAEL: 10 mg/kg body weight  
 Result: No teratogenic effects, No adverse effects

Test Type: Embryo-foetal development  
 Species: Rat  
 Application Route: Oral  
 Embryo-foetal toxicity: LOAEL: 60 mg/kg body weight  
 Result: Teratogenic potential  
 Remarks: Based on data from similar materials

**Magnesium stearate:**

Effects on fertility

: Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
 Species: Rat  
 Application Route: Ingestion  
 Method: OECD Test Guideline 422  
 Result: negative  
 Remarks: Based on data from similar materials

Effects on foetal development

: Test Type: Embryo-foetal development  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative  
 Remarks: Based on data from similar materials

## Ezetimibe / Simvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023  |
| 5.2     | 06.04.2024     | 28136-00023 | Date of first issue: 04.11.2014 |

---

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

Causes damage to organs (Liver, muscle, optic nerve, Eye) through prolonged or repeated exposure.

**Components:****Simvastatin:**

|               |   |   |
|---------------|---|---|
| Target Organs | : | Liver, muscle, optic nerve, Eye                                 |
| Assessment    | : | Causes damage to organs through prolonged or repeated exposure. |

**Repeated dose toxicity****Components:****Cellulose:**

|                   |   |                |
|-------------------|---|----------------|
| Species           | : | Rat            |
| NOAEL             | : | >= 9,000 mg/kg |
| Application Route | : | Ingestion      |
| Exposure time     | : | 90 Days        |

**Ezetimibe:**

|                   |   |  |
|-------------------|---|--|
| Species           | : | Dog  |
| NOAEL             | : | 1,000 mg/kg                                  |
| Application Route | : | Oral   |
| Exposure time     | : | 90 d   |
| Remarks           | : | No significant adverse effects were reported |

|                   |   |  |
|-------------------|---|--|
| Species           | : | Rat  |
| NOAEL             | : | 1,500 mg/kg                                  |
| Application Route | : | Oral   |
| Exposure time     | : | 90 d   |
| Remarks           | : | No significant adverse effects were reported |

|                   |   |  |
|-------------------|---|--|
| Species           | : | Mouse  |
| NOAEL             | : | 500 mg/kg                                    |
| Application Route | : | Oral   |
| Exposure time     | : | 90 d   |
| Remarks           | : | No significant adverse effects were reported |

|                   |   |  |
|-------------------|---|--|
| Species           | : | Dog  |
| NOAEL             | : | 300 mg/kg                                    |
| Application Route | : | Oral   |
| Exposure time     | : | 1 yr   |
| Remarks           | : | No significant adverse effects were reported |

**Simvastatin:**

|         |   |     |
|---------|---|-----|
| Species | : | Rat |
|---------|---|-----|

## Ezetimibe / Simvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023  |
| 5.2     | 06.04.2024     | 28136-00023 | Date of first issue: 04.11.2014 |

---

NOAEL : 5 mg/kg  
 LOAEL : 30 mg/kg  
 Application Route : Oral  
 Exposure time : 14 - 104 Weeks  
 Target Organs : Liver, Testis, Musculo-skeletal system, Eye

Species : Dog  
 LOAEL : 10 mg/kg  
 Application Route : Oral  
 Exposure time : 14 - 104 Weeks  
 Target Organs : Liver, Testis, Eye

Species : Rabbit  
 NOAEL : 30 mg/kg  
 LOAEL : 50 mg/kg  
 Application Route : Oral  
 Target Organs : Liver, Kidney

**Magnesium stearate:**

Species : Rat  
 NOAEL : > 100 mg/kg  
 Application Route : Ingestion  
 Exposure time : 90 Days  
 Remarks : Based on data from similar materials

**Aspiration toxicity**

Not classified based on available information.

**Components:****Ezetimibe:**

Not applicable

**Experience with human exposure****Components:****Ezetimibe:**

Ingestion : Symptoms: Headache, Nausea, Vomiting, Diarrhoea, flatulence, muscle pain, upper respiratory tract infection, Back pain, joint pain

**Simvastatin:**

Skin contact : Remarks: May produce an allergic reaction.  
 Ingestion : Target Organs: Liver  
 Symptoms: upper respiratory tract infection, Headache, Abdominal pain, constipation, Nausea  
 Target Organs: Musculo-skeletal system

## Ezetimibe / Simvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023  |
| 5.2     | 06.04.2024     | 28136-00023 | Date of first issue: 04.11.2014 |

---

## Section 12: Ecological information

**Toxicity****Components:****Cellulose:**

Toxicity to fish : LC50 (*Oryzias latipes* (Japanese medaka)): > 100 mg/l  
 Exposure time: 48 h  
 Remarks: Based on data from similar materials

**Ezetimibe:**

Toxicity to fish : LC50 (*Pimephales promelas* (fathead minnow)): > 0.125 mg/l  
 Exposure time: 96 h  
 Method: OECD Test Guideline 203  
 Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates : EC50 (*Daphnia magna* (Water flea)): > 4 mg/l  
 Exposure time: 48 h  
 Method: OECD Test Guideline 202  
 Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : EC50 (*Pseudokirchneriella subcapitata* (green algae)): > 0.317 mg/l  
 Exposure time: 96 h  
 Method: OECD Test Guideline 201  
 Remarks: No toxicity at the limit of solubility

NOEC (*Pseudokirchneriella subcapitata* (green algae)): 0.317 mg/l  
 Exposure time: 96 h  
 Method: OECD Test Guideline 201  
 Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity) : NOEC (*Pimephales promelas* (fathead minnow)): 0.051 mg/l  
 Exposure time: 33 d  
 Method: OECD Test Guideline 210

NOEC (*Cyprinodon variegatus* (sheepshead minnow)): 4 mg/l  
 Exposure time: 7 d  
 Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (*Daphnia magna* (Water flea)): 0.282 mg/l  
 Exposure time: 21 d  
 Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic toxicity) : 1

Toxicity to microorganisms : EC50: > 4.4 mg/l  
 Exposure time: 3 h  
 Test Type: Respiration inhibition



## Ezetimibe / Simvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023  |
| 5.2     | 06.04.2024     | 28136-00023 | Date of first issue: 04.11.2014 |

---

Method: OECD Test Guideline 209  
Remarks: No toxicity at the limit of solubility

NOEC: 4.4 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209  
Remarks: No toxicity at the limit of solubility

**Simvastatin:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 2.91 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 3.5 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 25 mg/l  
Exposure time: 96 h

NOEC (Pseudokirchneriella subcapitata (green algae)): 25 mg/l  
Exposure time: 96 h

Toxicity to microorganisms : EC50: > 30 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

NOEC: 21 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

**Magnesium stearate:**

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l  
Exposure time: 48 h  
Method: DIN 38412  
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l  
Exposure time: 47 h  
Test substance: Water Accommodated Fraction  
Method: Directive 67/548/EEC, Annex V, C.2.  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l

## Ezetimibe / Simvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023  |
| 5.2     | 06.04.2024     | 28136-00023 | Date of first issue: 04.11.2014 |

---

Exposure time: 72 h  
 Test substance: Water Accommodated Fraction  
 Method: OECD Test Guideline 201  
 Remarks: Based on data from similar materials  
 No toxicity at the limit of solubility

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l

Exposure time: 72 h  
 Test substance: Water Accommodated Fraction  
 Method: OECD Test Guideline 201  
 Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l  
 Exposure time: 16 h  
 Test substance: Water Accommodated Fraction  
 Remarks: Based on data from similar materials

**Persistence and degradability****Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

**Ezetimibe:**

Biodegradability : Result: Not readily biodegradable.  
 Biodegradation: 6.8 %  
 Exposure time: 28 d

Stability in water : Hydrolysis: 50 %(4.5 d)  
 Method: OECD Test Guideline 111

**Simvastatin:**

Biodegradability : Result: rapidly degradable

Stability in water : Hydrolysis: 50 %(3.2 d)

**Magnesium stearate:**

Biodegradability : Result: Not biodegradable  
 Remarks: Based on data from similar materials

**Bioaccumulative potential****Components:****Ezetimibe:**

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)  
 Bioconcentration factor (BCF): 173

## Ezetimibe / Simvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023  |
| 5.2     | 06.04.2024     | 28136-00023 | Date of first issue: 04.11.2014 |

---

Exposure time: 97 d  
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.36

**Simvastatin:**

Partition coefficient: n-octanol/water : log Pow: > 4.07

**Magnesium stearate:**

Partition coefficient: n-octanol/water : log Pow: > 4

**Mobility in soil****Components:****Ezetimibe:**

Distribution among environmental compartments : log Koc: 4.35  
Method: OECD Test Guideline 106

**Other adverse effects**

No data available

**Section 13: Disposal considerations****Disposal methods**

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

**Section 14: Transport information****International Regulations****UNRTDG**

UN number : UN 3077  
UN proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(Ezetimibe, Simvastatin)

Transport hazard class(es) : 9  
Packing group : III  
Labels : 9  
Environmental hazards : yes

**IATA-DGR**

UN/ID No. : UN 3077  
UN proper shipping name : Environmentally hazardous substance, solid, n.o.s.  
(Ezetimibe, Simvastatin)

## Ezetimibe / Simvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023  |
| 5.2     | 06.04.2024     | 28136-00023 | Date of first issue: 04.11.2014 |

---

Transport hazard class(es) : 9  
 Packing group : III  
 Labels : Miscellaneous  
 Packing instruction (cargo aircraft) : 956  
 Packing instruction (passenger aircraft) : 956  
 Environmentally hazardous : yes

**IMDG-Code**

UN number : UN 3077  
 Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Simvastatin)

Transport hazard class(es) : 9  
 Packing group : III  
 Labels : 9  
 EmS Code : F-A, S-F  
 Marine pollutant : yes

**Transport in bulk according to IMO instruments**

Not applicable for product as supplied.

**Special precautions for user**

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

**Section 15: Regulatory information****Safety, health and environmental regulations specific for the product in question**

Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subjected to the SDS, labelling, PEL and other requirements in the Act/Regulations.

Environmental Protection and Management Act and Environmental Protection and Management (Hazardous Substances) Regulations : Not applicable

Fire Safety (Petroleum and Flammable Materials) Regulations : Not applicable

**The components of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

**Section 16: Other information**

## Ezetimibe / Simvastatin Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023  |
| 5.2     | 06.04.2024     | 28136-00023 | Date of first issue: 04.11.2014 |

---

Revision Date : 06.04.2024

**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

**Full text of other abbreviations**

ACGIH : USA. ACGIH Threshold Limit Values (TLV)  
 SG OEL : Singapore. Workplace Safety and Health (General Provisions) Regulations - First Schedule Permissible Exposure Limits of Toxic Substances.

ACGIH / TWA : 8-hour, time-weighted average  
 SG OEL / PEL (long term) : Permissible Exposure Level (PEL) Long Term

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only

# SAFETY DATA SHEET



## Ezetimibe / Simvastatin Formulation



|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023  |
| 5.2     | 06.04.2024     | 28136-00023 | Date of first issue: 04.11.2014 |

---

to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SG / EN